Abstract
Respiratory syncytial virus (RSV) infections are a major public health concern for pediatric populations and older adults. Viral kinetics, the dynamic processes of viral infection within an individual over time, vary across different populations. However, RSV transmission in different age groups is incompletely understood from the perspective of individual-level viral kinetics. To explore how individual viral kinetics can be related to RSV transmission, we first fitted a mathematical model to longitudinal viral kinetic data from 53 individuals in pediatric, adult, and elderly age groups using a hierarchical Bayesian framework to estimate important viral kinetic parameters. Using a probabilistic model, we then related the within-host viral load to the probability of transmission for each age group. We found that children had higher peak viral loads and longer shedding periods compared to other age groups, suggesting a higher transmission probability in children over the infectious period. We validated our findings by comparing the estimated secondary attack rate across different age groups to empirical estimates from household transmission studies. Our work highlights the importance of age-specific considerations in understanding and managing RSV infections, suggesting that age-targeted interventions will be more effective in controlling RSV transmission.
Summary We utilized within-host viral load kinetics data to infer the transmission potential of RSV infection across different age groups, revealing the highest transmission probability in the pediatric group.
Competing Interest Statement
DMW has received consulting fees from Pfizer, Merck, and GSK, unrelated to this manuscript, and has been PI on research grants from Pfizer and Merck to Yale, unrelated to this manuscript. The other authors declare no competing interests.
Funding Statement
This work was supported by a grant from the National Institutes of Health (R01AI137093). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally published in previous studies (see Data source in the manuscript).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
